Introduction {#Sec1}
============

Breast cancer is a growing concern worldwide as the leading cause of mortality and morbidity among women in developed and developing countries \[[@CR1]\]. It has been predicted that the worldwide incidence of breast cancer will reach approximately 3.2 million new cases per year by 2050 \[[@CR2]\]. Approximately 60% of deaths due to breast cancer occur in developing countries \[[@CR3]\]. Cancer incidence in Ethiopia has been increasing over time and breast cancer is the most prevalent malignancy (30.2%) followed by cancer of the cervix (13.4%) and colorectal cancer (5.7%) among adults \[[@CR4]\]. Consequently, cancer is emerging as a critical public health problem in Ethiopia \[[@CR5], [@CR6]\].

The impact of cancer, however, is far greater than the number of cases would suggest. Patients with breast cancer experience physical symptoms and psychosocial distress that adversely affect their health-related quality of life (HRQoL). The World Health Organization defined HRQoL as involving a person's physical health, psychological state, degree of independence, social relationships, personal beliefs and environment \[[@CR7]\]. HRQoL measures wellbeing related to or affected by the presence of a disease or treatments and it generally consists of a number of domains including physical functioning, psychological well-being (such as levels of anxiety and depression), and social support \[[@CR8]\]. Ongoing symptoms, side effects of treatments, recurrence often result in a feeling of distress that affects physical and psychological functioning and impacts on lifestyle and social engagements of patients with breast cancer \[[@CR9]\]. Patients receiving chemotherapy might also experience several side-effects and symptoms that negatively affect their HRQoL \[[@CR10]\].

Deterioration of patients' HRQoL is more pronounced in developing counties since breast cancer is diagnosed at advanced stages and as a result, treatment cannot be efficiently executed \[[@CR3]\]. As breast cancer is the leading cause of morbidity and mortality among women with cancer in Ethiopia, HRQoL among patients with breast cancer is given minimal attention. Thus, assessing HRQoL, associated factors and utility would be helpful to inform interventions and improves patient outcome \[[@CR11]\].

Methods {#Sec2}
=======

Study setting {#Sec3}
-------------

The study was conducted at Tikur Anbessa Specialized Hospital (TASH), the largest teaching hospital under the administration of Addis Ababa University in Ethiopia. The hospital was established in 1972 and has more than 800 beds providing diagnostic and treatment service for about 370,000 to 400,000 patients per year. The oncology unit at TASH is the largest referral site for the country, providing service for over 60,000 patients annually. It is the sole oncology referral and radiotherapy center in the entire country \[[@CR12]\].

Study variables {#Sec4}
---------------

### **Dependent variables**: GQoL, functional scales, symptom scales {#Sec5}

**Independent variables**: Socio-demographic characteristics such as age, marital status, level of education, and average monthly household income (AMHI).Clinical characteristics such as patient status, time since diagnosis, stage of cancer, current type of anticancer treatment and comorbid conditions.Functional scalesSymptom scales

### Study design and participants {#Sec6}

We conducted a hospital-based cross-sectional study in patients with breast cancer at the outpatient oncology unit of TASH between December 2017 and February 2018. The sample size was calculated using the single proportion formula \[[@CR13]\]. Due to absence of studies done using Euro Quality of Life Group's 5-Domain Questionnaires 5 Levels (EQ-5D-5 L) and with the intention of obtaining maximum sample size, an estimate proportion of patients that have utility values above the average was considered to be 50%, was used to calculate the sample size. $$\documentclass[12pt]{minimal}
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Where: **n** = required sample size.

**Z**~**α\ /2**~ = 1.96 (Z = score corresponds to 95% confidence level).

**P** = proportion of patients with utility above the average.

**d**^**2**^ = margin of error (0.05) $$\documentclass[12pt]{minimal}
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Considering a 5% of contingency for inappropriate and nonresponses, finally we interviewed a total of 404 patients. Since we used a face-to-face interview, all eligible patients approached were willing to participate in the study and none of the patient data were incomplete. Participants were recruited consecutively until the required sample size was reached.

Female patients pathologically diagnosed with breast cancer; both new and follow up were eligible for the study. Patients who were pregnant, critically ill (too weak to communicate, as per the assessment of oncologist), have a psychiatric disorder, can't speak and/or read Amharic language, or are unwilling to participate in the study were excluded.

Data was collected by two trained oncology nurses working within the oncology clinic. Two days training was given for the oncology nurses focusing on; the contents of the questionnaire, the identification of patients based on the inclusion/exclusion criteria, and how to get consent. Participants were assured of anonymity and confidentiality of their information obtained in the study by excluding any personal identifier in the data collection form. They were also reassured that the report of the findings would not identify them and only the aggregate data would be reported. All the collected data were checked for completeness by the principal investigator on a daily basis.

### Instruments and scoring {#Sec7}

We used the validated Amharic version (official language of Ethiopia and the study area) of three data collection instruments: *EORTC QLQ-C30, EORTC QLQ-BR23 and EQ-5D-5 L* (Additional file [1](#MOESM1){ref-type="media"})*.* i.***EORTC QLQ-C30:*** The EORTC QLQ-C30 consists of five functional scales (physical, emotional, role, cognitive, and social functioning), nine symptom scales (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties) and the GQoL scale, which aims to provide a multidimensional assessment of the HRQoL of patients based on 28 questions using a four-point scale. Two additional questions were used to determine the state of health on a seven-point Likert scale. Each of the multi-item scales includes a different set of items, no item occurs in more than one scale \[[@CR14]\].ii.***EORTC QLQ-BR23:*** The side-effects of therapy and tumour-related symptoms in patients with breast cancer was determined and recorded using the additional EORTC QLQ-BR23 module, which consists of 23 questions distributed across eight (sexual functioning, future perspective, body image, sexual enjoyment, systemic therapy, breast symptoms, arm symptoms, and upset by hair loss) with a four-point scales; from 1 = not at all to 4 = very much \[[@CR14]\].iii.***EQ-5D-5 L:***The generic EQ-5D-5 L questionnaire assessed the HRQoL across five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), with a 5-level response (from 1 = no problem to 5 = extreme problem) and the EQ-VAS scale on which the overall state of health is marked by the patient in the form of a number (0 = worst imaginable state of health, 100 = best imaginable state of health). The utility value between the worst and best health state is on a scale from 0 to 1, where 0 denotes death and 1 denotes perfect health. EQ-5D-5 L is highly discriminatory, easy to use and can generate a single total score based on socially relevant measures of HRQoL \[[@CR15]\].

Both EORTC QLQ-C30 and EORTC QLQ-BR23 are composed of both multi-item scales and single-item measures. Each of the multi-item scales includes a different set of items, no item occurs in more than one scale. The principle for scoring the EORTC QLQ-C30 and EORTC QLQ-BR23 scales is the same in all cases which starts with estimating the average of the items that contribute to the scale (raw score) and using a linear transformation to standardize the raw score. Scores range from 0 to 100; a higher score represents a higher ("better") level of functioning, or a higher ("worse") level of symptoms \[[@CR14]\]. The two items for the scales are scored positively (i.e. "very much" is best) and therefore use the same algebraic equation as for symptom scales which is reversely coded; however, the Body Image scale uses the algebraic equation for functioning scales \[[@CR16]\].

### Data analysis and interpretation {#Sec8}

Statistical analysis was undertaken using SPSS 23.0. Analyzing the data, responses were reverse coded as appropriate. Simple descriptive statistics such as frequencies, means, and standard deviations (SD) were employed to report the socio-demographic characteristics, clinical characteristics, EORTC QLQ-C30, EORTC QLQ-BR23, EQ-5D-5 L, and EQ VAS scores. Multivariable logistic regression was carried out to identify possible predicting factors for GQoL. GQoL, symptom and functional scales have been dichotomized into "Affected at any degree" and "Not affected at all". A score below 75 (above 75 mean no problem at all) for functional and GQoL scales were defined as "Affected at any degree". Scores above a 25 mean (below 25 indicates no symptom at all) were defined as "Affected at any degree" and binary logistic regression was conducted between the GQoL and independent variables to obtain candidate variables for multi-variable logistic regression analysis. Variables with *p*-value \< 0.25 were candidate for multiple regression analysis. Due to many independent variables, forward stepwise method was used for the multivariable analysis and significance of association was determined at *p*-value \< 0.05. Patient's utility score is obtained using possible (3125) health states of patients with breast cancer defined by the 5 dimensions and disutility coefficient of general population. Thus, it was calculated using the Ethiopian general population utility value set \[[@CR17]\]. One caveat in order is the limitation within the analysis where causality of the associations was not confirmed.

Results {#Sec9}
=======

Socio-demographic and clinical characteristics of patients {#Sec10}
----------------------------------------------------------

All 404 patients completed the questionnaires, i.e., there were no missing responses. Patients' mean age was 43.94 ± 11.72 years and more than two-thirds of patients (70.2%) attended formal education. The average monthly household income (AMHI) was 2634 ± 3373 Ethiopian Birr (\$1 = 27.4ETB) and one-third of patients (31.9%) had an AMHI of ≤600 ETB. The majority (89.4%) of patients were on follow-up and more than half (52.7%) were diagnosed within the past year. Regarding the severity of disease, 142 (35.1%) and 134 (33.2%) of patients with breast cancer were in cancer stage III and II, respectively. Most patients (52.5%) received surgical treatment and 318 (78.7%) had no comorbid conditions (Table [1](#Tab1){ref-type="table"}). Table 1Socio-demographic and clinical characteristics of patients with Breast cancer at TASH, Addis Ababa, EthiopiaStudy Variablesn (%)Age (years) 15--243 (0.7) 25--54320 (79.2) 55--6457 (14.1)  \> 6524 (5.9)Marital status Single56 (13.9) Married232 (57.4) Divorced56 (13.9) Widowed60 (14.9)Level of education Illiterate (neither read nor write)92 (22.8) Informal education28 (6.9) Primary education76 (18.8) Secondary education123 (30.4) Higher education (certificate, diploma, and above)85 (21.0)AMHI, in ETB  ≤ 600129 (31.9)  \> 600275 (68.1)Patient status New patient43 (10.6) Follow up361 (89.4)Time since diagnosis (months)  \< 12 months213 (52.7) 13--60 months154 (38.1)  \> 61 months37 (9.2)Stage of cancer Stage I13 (3.2) Stage II134 (33.2) Stage III142 (35.1) Stage IV84 (20.8) Undefined31 (7.7)Current treatment Surgery212 (52.5) Chemotherapy24 (5.9) Hormonal therapy139 (34.4) Radiotherapy29 (7.2)Comorbid conditions Yes86 (21.3) No318 (78.7)

### Global quality of life {#Sec11}

The GQoL mean score was 59.32 ± 22.94. Functional scale mean scores ranged from 67.97 ± 25.15 for physical functioning to 80.07 ± 30.08 for social functioning. All the symptom scales and items except for nausea/vomiting, dyspnea, constipation, and diarrhea scored above 25. With regard to EORTC QLQ-BR23 functioning scales/items, body image was the highest score (77.21 ± 32.09), while sexual functioning recorded the lowest score (17.78 ± 28.09). Except for breast symptoms and arm symptoms, all others scored above 25 for the symptom scales and items (Table [2](#Tab2){ref-type="table"}). Table 2Mean score value of the EORTC QLQ-C30 and EORTC QLQ-BR23 Scales Variables of patients with Breast cancer at TASH, Addis Ababa, EthiopiaEORTC QLQ-C30 and EORTC QLQ-BR23 ScalesMean ± SDEORTC QLQ- C30GQoL59.32 ± 22.94Functional scales Physical functioning67.97 ± 25.15 Role functioning73.18 ± 36.19 Emotional functioning71.51 ± 29.74 Cognitive functioning78.55 ± 26.23 Social functioning80.07 ± 30.08Symptom scales and Items Fatigue42.38 ± 33.35 Nausea and Vomiting14.48 ± 24.96 Pain36.46 ± 32.91 Dyspnoea18.65 ± 30.69 Insomnia33.16 ± 39.85 Appetite loss36.47 ± 40.69 Constipation24.83 ± 35.72 Diarrhea4.04 ± 14.76 Financial Difficulties48.59 ± 44.56EORTC QLQ-BR23Functional scales Body image77.21 ± 32.09 Sexual functioning17.78 ± 28.09 Sexual enjoyment63.51 ± 30.98 Future perspective52.47 ± 43.13Symptom scales/items Systemic therapy side effects34.11 ± 22.59 Breast symptoms18.39 ± 22.71 Arm symptoms24.92 ± 25.06 Upset by hair loss26.92 ± 40.24

### Mean differences of EORTC QLQ-C30 and EORTC QLQ-BR23 scales with socio-demographic and clinical characteristics {#Sec12}

Family income showed a significant mean difference with GQoL, physical functioning and role functioning on the functional scales. Similarly, family income showed significant mean differences with constipation and financial difficulties on the symptom scales. The other socio-demographic variables, however, showed no significant mean difference with EORTC QLQ-C30. Moreover, patients with stage 4 cancer scored the lowest mean in GQoL, physical function and role functioning. Type of treatment showed a significant mean difference and those who were treated with radiotherapy scored the lowest mean in their GQoL, role functioning, emotional functioning and cognitive functioning. Stage 4 cancer patients had a higher mean score on fatigue, nausea and vomiting, pain, dyspnea, insomnia and appetite loss except for diarrhea and financial difficulties. Patients who took chemotherapy had a higher score in nausea and vomiting, appetite loss and diarrhea while those who took radiotherapy had a higher score on pain. However, the other symptom scales were not significant with treatment and comorbid conditions (Additional file [2](#MOESM2){ref-type="media"}). Further details are presented in Additional file [2](#MOESM2){ref-type="media"}.

### Factors of quality of life {#Sec13}

In multivariable analysis, five variables (stage of cancer, cognitive functioning, pain, financial difficulties, and future perspective) were found to be significantly associated with patients' GQOL (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}). Only cancer stage maintained a significant association with the socio-demographic and clinical characteristics. This implied that stage 4 breast cancer patients were 7.94 times more likely that their GQoL was affected by cancer (Table [3](#Tab3){ref-type="table"}). Table 3Association of socio-demographic/economic factors with GQoL of patients with breast cancer at TASH, Addis Ababa, EthiopiaVariablesGQoLCOR (95% CI)AOR (95% CI)AffectedNot affectedSocio-demographic/economicEducational status Illiterate69 (25.1)23 (17.8)1.00 Informal21 (7.6)7 (5.5)1.00 (0.38--2.66) Primary56 (20.4)20 (15.5)0.93 (0.47--1.87) Secondary84 (30.5)39 (30.2)0.72 (0.39--1.32) Higher45 (16.4)40 (31.0)0.38 (0.19--0.71)AMHI ≤600100 (36.4)29 (22.5)1.00 \> 600175 (63.6)100 (77.5)0.51 (0.31--0.82)Clinical characteristicsStage of cancer Stage 17 (2.6)6 (4.7)1.00 Stage 286 (31.3)48 (37.3)1.54 (0.49--4.83)3.09 (0.79--12.09) Stage 393 (33.8)49 (38.0)1.63 (0.52--5.11)3.08 (0.79--12.01) Stage 471 (25.8)13 (10.0)4.68 (1.35--16.18)7.94 (1.83--34.54) \* Undefined18 (6.5)13 (10.0)1.19 (0.32--4.37)2.04 (0.43--9.61)Current Treatment Chemo therapy151 (54.9)61 (47.3)1.00 Surgery15 (5.5)9 (6.9)0.67 (0.28--1.62) Hormonal therapy85 (30.9)54 (41.9)0.64 (0.40--0.99) Radiotherapy24 (8.7)5 (3.9)1.94 (0.71--5.32) Table 4Association between (EORTC QLQ-C30, EORTC QLQ-BR23) functioning and symptom scales with GQoL of patients with breast cancer at TASH, Addis Ababa, EthiopiaVariableGQOLCOR (95% CI)AOR (95% CI)AffectedNot affectedEORTC QLQ C-30Functional scales Physical functioningAffected187 (68.0)46 (35.7)3.83 (2.47--5.96)Not affected88 (32.0)83 (64.3)1.00 Role FunctioningAffected139 (50.5)18 (14.0)6.30 (3.63--10.94)Not affected136 (49.5)111 (86.0)1.00 Emotional FunctioningAffected134 (48.7)30 (23.3)3.14 (1.96--5.03)Not affected141 (51.3)99 (76.7)1.00 Cognitive FunctioningAffected121 (44.0)23 (17.8)3.62 (2.18--6.03)2.38 (1.32--4.31)\*Not affected154 (56.0)106 (82.2)1.001.00 Social FunctioningAffected104 (37.8)27 (20.9)2.29 (1.41--3.75)Not affected171 (62.2)102 (79.1)1.00Symptom scales FatigueAffected204 (74.2)45 (34.9)5.36 (3.41--8.43)Not affected71 (25.8)84 (65.1)1.00 Nausea and VomitingAffected87 (31.6)14 (10.9)3.80 (2.07--6.99)Not affected188 (68.4)115 (89.1)1.00 PainAffected195 (70.9)26 (20.2)9.66 (5.84--15.96)7.99 (4.62--13.83)\*Not affected80 (29.1)103 (79.8)1.001.00 DyspnoeaAffected113 (41.1)18 (14.0)4.30 (2.47--7.48)Not affected162 (58.9)111 (86.0)1.00 InsomniaAffected152 (55.3)37 (28.7)3.07 (1.96--4.82)Not affected123 (44.7)92 (71.3)1.00 Appetite lossAffected166 (60.4)38 (29.5)3.65 (2.33--5.72)Not affected109 (39.6)91 (70.5)1.00 ConstipationAffected122 (44.4)35 (27.1)2.14 (1.36--3.38)Not affected153 (55.6)94 (72.9)1.00 DiarrheaAffected27 (9.8)7 (5.4)1.89 (0.80--4.48)Not affected248 (90.2)122 (94.6)1.00 Financial DifficultiesAffected187 (68.0)54 (41.9)2.95 (1.92--4.55)2.60 (1.56--4.35)\*Not affected88 (32.0)75 (58.1)1.001.00EORTC QLQ BR-23Functional scales Sexual functioningAffected70 (25.5)50 (38.8)0.54 (0.35--0.84)Not affected205 (74.5)79 (61.2)1.00 Future PerspectiveAffected181 (65.8)61 (47.3)2.15 (1.40--3.29)2.08 (1.24--3.49)\*Not affected94 (34.2)68 (52.7)1.001.00Symptom scales Systemic therapy side effectsAffected184 (66.9)44 (34.1)3.91 (2.51--6.08)Not affected91 (33.1)85 (65.9)1.00 Breast SymptomsAffected109 (39.6)24 (18.6)2.87 (1.73--4.76)Not affected166 (60.4)105 (81.4)1.00 Arm symptomsAffected119 (43.3)28 (21.7)2.75 (1.70--4.46)Not affected156 (56.7)101 (78.3)1.00AOR Adjusted Odd's Ratio, COR crudes Odd's Ratio

For EORTC QLQ-C30, only cognitive functioning was significant. Thus, patients GQoL was 2.38 times more likely to be affected if they reported problems with cognitive functioning. Among the symptom scale variables, pain and financial difficulties maintained their association in the multivariable analysis. Patients GQoL was 8 times more likely to be affected if they reported problems with pain. Patients GQoL was 2.60 times more likely to be affected if they reported problems with financial difficulties. For the breast specific EORTC QLQ-BR23 of the functional scales, only future perspective maintained the association in the multi-variable analysis (AOR = 2.08;95% CI: 1.24--3.49) (Table [4](#Tab4){ref-type="table"}).

### EQ-5D dimensions affected by breast Cancer and utility score {#Sec14}

For the EQ-5D-5 L, except for pain variable, more than half of the patients had no problem in any of the five dimensions. The study showed that 23.8, 4.2, and 1% of the patients reported slight to moderate, severe mobility problem, and unable to walk, respectively. According to the study, 9.9% of them reported a slight to moderate self-care problem while 1.7% of them were unable to wash or dress themselves. Regarding daily activities, 27.4% of the patients reported that they experienced slight to moderate problems in their daily activity with 3.5% were unable to do their usual activities. 43.3% of the patients reported that they suffered slight to moderate pain, 6.9% suffered a severe pain and 4.5% suffered an extreme pain. Considering depression/anxiety, 30.2, 7.4, and 2.7% of the patients suffered a slight to moderate, severe, and an extreme anxiety/depression, respectively (Fig. [1](#Fig1){ref-type="fig"}).The mean score for the EQ-VAS was 69.94 ± 20.36, while the mean utility score was found to be 0.8 ± 0.25., which translates to patients with breast cancer preferred to trade-off 2 years of live and preferred to live 8 years in full health compared to living 10 years with their current health status. Fig. 1Frequency distribution of the five-dimensional EQ-5D-5 L questionnaire of patients with Breast cancer at TASH, Addis Ababa, Ethiopia, 2018

Discussion {#Sec15}
==========

The purpose of the study was to assess HRQoL, predicting factors and utility among patients with breast cancer in TASH. In the assessment of functioning scales, the lowest score was found for physical and sexual functioning. Highest symptom scales were found for fatigue, pain, loss of appetite and systemic therapy side effects were reported. The mean score for GQoL was 59.32 ± 22.94 which is almost similar to studies conducted in Iran, Central rural India, Germany and Lebanon \[[@CR10], [@CR18]--[@CR20]\]. Our finding, however, was lower than the EORTC reference value (61.8 ± 24.6) \[[@CR21]\] and studies conducted in South India, Australia, UK, Bahrain, Jordan, and Latin America \[[@CR21]--[@CR26]\]. This could be due to limited understanding of the disease, the lengthy process of referral to the country's only specialized center, and late presentation; with most patients at the center diagnosed in a metastasized level which makes the disease incurable \[[@CR27]\].

Physical and cognitive functioning were lower than the reference value, whereas role, emotional and social functioning were higher than the reference value \[[@CR28]\]. Symptom scales of the EORTC-C30 were higher than the reference value except for diarrhea, which implied that the patient with breast cancer were very symptomatic. Fatigue and financial difficulties were the highest complaints. The mean score of financial difficulties of this study were higher than studies conducted in Nepal, Iran, Kuwait and Nigeria \[[@CR10], [@CR29]--[@CR31]\]. The current study also showed that household income had a significant mean difference with GQoL, and 31.9% of the study participants were below the poverty line \[[@CR32]\]. And since TASH is a destination for patients from every corner of the country, transport and hospitality fees in Addis Ababa are not easily affordable, and this could have contributed to the higher scores of financial difficulties \[[@CR6]\].

Regarding the breast specific assessment tool, the mean results of the functional and symptom subscales in this study were higher than results of the studies conducted in Kuwait and Morocco \[[@CR30], [@CR33]\] but lower than studies conducted in south India, Germany, UK, Bahrain, Iran, and Latin \[[@CR10], [@CR19], [@CR22], [@CR24]--[@CR26]\]. The burden of breast cancer in Ethiopian women may be higher because of limited healthcare access with only a single radiotherapy center in the country \[[@CR6]\]. This might exacerbate symptoms because of long waiting times. This might be also attributed to a limited psychological support for breast cancer patients in the Ethiopian health care system and community.

Pain was the major predictor factor of GQoL; the significant mean difference showed that stage 4 breast cancer patients and patients who were on chemotherapy and radiotherapy had higher mean result. The current results from the EQ-5D-5 L also support that pain is a major complaint among breast cancer patients in TASH. A study conducted in Ethiopia also reported the inadequacy of cancer pain management \[[@CR34]\]. Another study also suggested that early symptom screening should be incorporated into nursing assessment procedures for a better outcome \[[@CR35]\].

Cancer Stage 4 was found to be one of the GQoL predictors. A significant mean difference was also seen between GQoL and stage 4 patients. The association between cancer stage and GQoL were similar to a study conducted in Bahrain \[[@CR25]\]. Considering the access of cancer treatment in Ethiopia, Which is accompanied by long waiting time, it is difficult for a great majority of the population to access cancer treatment services. In Addition to that, the low awareness of cancer signs and symptoms, inadequate screening and early detection and treatment services, inadequate diagnostic facilities and country's very few cancer specialists, also results in many potentially curable tumors to progress to incurable stages \[[@CR6]\].

The present study indicated that cognitive functioning was one of the GQoL predictors and showed significant mean difference between cognitive functioning and treatment, which mirrors a study conducted in Tunisia \[[@CR36]\]. Cognitive functioning of patients could be compromised due to chemotherapy, pain and disease burden of patients \[[@CR37]\]. Patients at TASH could benefit from a follow up of investigation of cognitive functioning.

Patients whose physical condition or medical treatment caused them financial difficulties were a GQoL predictor. A study conducted in Kuwait also showed the importance of financial difficulties \[[@CR30]\]. Future perspective was found to be another predictor of the GQoL. This finding was in contrary with the study done in Kuwait, where about two-thirds of the patients were optimistic about their future health \[[@CR30]\]. This difference of future perspective could attribute to the lower awareness, improper understanding of the disease, associated stigma and sense of hopelessness of Ethiopian cancer patients \[[@CR27]\].

The health state determined using EQ-VAS was found to be higher than a study conducted in Germany and lower than a study conducted in Zimbabwe \[[@CR19], [@CR38]\]. And the utility mean score value of the patients with breast cancer was estimated to be 0.8, which is almost similar with Finnish populations (0.89) \[[@CR39]\]. Thus, the utility values have been used to make health economic evaluations and decisions relevant for better health outcome of patients \[[@CR40]\]. The current research can be used to inform patient care and future economic evaluation for breast cancer patients.

Therefore, the present study will fill the knowledge gap about the impact of socio-demographic and clinical factors on HRQoL among patients with breast cancer in the study setting. The study used a large sample size and validated measurement tools to assess the HRQoL. Furthermore, it will help healthcare providers to recognize the causes that affect HRQoL and identify the aspects of patient treatment protocol that needs to be enhanced to improve their HRQoL since its assessment is used to measure the outcome of medical intervention. It will mainly help for economic evaluation of existing and new chemotherapy drugs for patients with breast cancer.

Despite all its strengths, the study has certain limitations. Since the study was a cross-sectional study, it might limit assessment of prognosis of the patients. In addition, the study was conducted in a single setting, which might be difficult to make a generalization for the country.

Conclusion {#Sec16}
==========

The GQoL of breast cancer patients was below the population reference but comparable to other studies. The utility mean score was estimated to be above average (u = 0.8). HRQoL could be used to continuously monitor outcomes and focus should be given to pain management, and strengthening the insurance agency to improve access and affordability.
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